

Research Grants



Call for Proposals 2024:

Impact of age on the progression of multiple sclerosis

The German National Multiple Sclerosis (MS) Society, DMSG, Bundesverband e.V., is committed, along with physicians, scientists, people with MS, their relatives and interested stakeholders to promote research on multiple sclerosis. To this end, the DMSG provides an annual research funding program.

MS is usually diagnosed between the age of 20 and 40 years. Initial diagnoses occur with less frequency in childhood or adolescence. After the age of 60, MS is nowadays diagnosed at increased frequency and clearly more often than in the past. The prevalence in older age groups is also influenced by the increased, now normal life expectancy of MS patients, which has been achieved partly due to the progress in treatment in recent decades.

Young, middle or old age appears to be a significant factor not only in the individual diagnosis but also in the further progression of MS due to differences in the subsets of the immune system. Immune senescence may therefore have an age-dependent effect on disease activity. Also, severity of the inflammation in MS and the response to immunotherapies appear to be subject to age-related changes. Yet, the impact of age on the immune system and its components is by far not well understood.

This call for proposals is intended to promote research on the impact of age on the progression of MS to expand our knowledge of the etiology and pathogenesis on one hand and to advance the further development of diagnostics and therapy in the aging population of MS patients on the other hand.

Deadline November 30th, 2024

In an annual cycle (corresponding to the thematic framework of the respective call) excellent applied or clinical research projects will be funded for a maximum of 24 months. Funding can be granted up to 100,000 Euro per project and year. The number and approval of funded projects will depend on the available funds allocated for research purposes and approval by the Executive Committee. For this year's program funding will be possible at the earliest in May 2025.

Please send your full application documents by **November 30th, 2024** (application deadline) using the subject line: "Individual research project funding" to referat-gs@dmsg.de.

For further information regarding the application process and the independent peer review system, please refer to the guidelines to support research funded by DMSG, Bundesverband e.V. and to www.dmsg.de/unsere-aufgaben/wir-foerdern-die-forschung/.

We are looking forward to receiving your submission.

The DMSG-Research Grant for individual projects was supported 2023 i.a. by:
Bristol-Myers Squibb GmbH & Co. KGaA, Merck Healthcare Germany GmbH,
Novartis Pharma GmbH, Roche Pharma AG,
Sanofi Aventis GmbH, Viatrix Healthcare GmbH